Verano Holdings (VRNO) Income from Continuing Operations (2021 - 2026)
Verano Holdings (VRNO) reported Income from Continuing Operations of 17823000.0 for Q1 2026, down 54.78% year-over-year from 39414604.38 in Q1 2025, and up 90.28% quarter-over-quarter from 183411000.0 in Q4 2025.
Verano Holdings (VRNO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Income from Continuing Operations data on file, last reported at 17823000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 17823000.0, down 54.78% year-over-year; the trailing twelve-month figure through Mar 2026 was 264216000.0 (up 24.2% YoY), and the FY2025 annual result was 257908000.0, up 24.56% from the prior year.
- Income from Continuing Operations climbed to 17823000.0 in Q1 2026 per VRNO's latest filing, from 183411000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 45866000.0 in Q1 2022 and troughed at 272706000.0 in Q4 2024.
- A 5-year average of 56354235.29 and a median of 19150000.0 in 2025 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 66.72% in 2022 and fell as far as 3065.98% in 2022.
- A 5-year view of Income from Continuing Operations shows it stood at 216110000.0 in 2022, then soared by 64.24% to 77286000.0 in 2023, then plunged by 252.85% to 272706000.0 in 2024, then jumped by 32.74% to 183411000.0 in 2025, then soared by 90.28% to 17823000.0 in 2026.
- Business Quant data shows VRNO's Income from Continuing Operations at 17823000.0 in Q1 2026, 183411000.0 in Q4 2025, and 43832000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Verano Holdings | - | - | 98.98 Mn | -17.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.82 Mn |
| Dec 31, 2025 | -183.41 Mn |
| Sep 30, 2025 | -43.83 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -11.52 Mn |
| Dec 31, 2024 | -272.71 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -21.76 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | -77.29 Mn |
| Sep 30, 2023 | -17.76 Mn |
| Jun 30, 2023 | -13.06 Mn |
| Mar 31, 2023 | -9.24 Mn |
| Dec 31, 2022 | -216.11 Mn |
| Sep 30, 2022 | -42.99 Mn |
| Jun 30, 2022 | -9.85 Mn |
| Mar 31, 2022 | 45.87 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -11.96 Mn |
| Jun 30, 2021 | -29.59 Mn |